INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial

Inmune Bio, Inc.

XPro1595 showed significant myelin improvement vs placebo in full mITT (p=0.0028, d=0.46, n=200).
Biomarker-enriched patients (inflammation) showed stronger effect (p=0.0098, d=0.59, n=100).
FDA granted Fast Track designation on May 14, 2026; End-of-Phase 2 alignment secured for Phase 2b/3.
No ARIA-E or ARIA-H observed; favorable safety profile differentiates from amyloid-targeting therapies.
Complete dataset to be presented at AAIC 2026 (July 12-15, London).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.